Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.

Ligtenberg MA, Pico de Coaña Y, Shmushkovich T, Yoshimoto Y, Truxova I, Yang Y, Betancur-Boissel M, Eliseev AV, Wolfson AD, Kiessling R.

Mol Ther. 2018 Jun 6;26(6):1482-1493. doi: 10.1016/j.ymthe.2018.04.015. Epub 2018 Apr 13.

2.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14.

3.

Gravity-Drawn Silicone Filaments: Production, Characterization, and Wormlike Chain Dynamics.

Kiessling R, Rubin SJS, Zehner J, Barraugh C, Snell K, Fukushima C, Mulligan M, Keckley M, Bosshardt A, Cook W, Sanii B.

ACS Appl Mater Interfaces. 2017 Nov 22;9(46):39916-39920. doi: 10.1021/acsami.7b11972. Epub 2017 Nov 10.

PMID:
29111635
4.

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Laurell A, Lönnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling R, Karlsson-Parra A.

J Immunother Cancer. 2017 Jun 20;5:52. doi: 10.1186/s40425-017-0255-0. eCollection 2017.

5.

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.

Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Masucci G, Karlsson-Parra A, Lundqvist A, Adamson L, Kiessling R.

Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344. doi: 10.1007/s00262-017-2029-4. Epub 2017 Jun 10.

6.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R.

Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368.

7.

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E.

Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242. eCollection 2017.

8.

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.

Eissler N, Mao Y, Brodin D, Reuterswärd P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P.

Oncoimmunology. 2016 Sep 9;5(12):e1232222. doi: 10.1080/2162402X.2016.1232222. eCollection 2016.

9.

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.

Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J.

J Transl Med. 2016 Jul 29;14(1):227. doi: 10.1186/s12967-016-0983-9.

10.

Cripto-1 vaccination elicits protective immunity against metastatic melanoma.

Ligtenberg MA, Witt K, Galvez-Cancino F, Sette A, Lundqvist A, Lladser A, Kiessling R.

Oncoimmunology. 2016 Jan 8;5(5):e1128613. doi: 10.1080/2162402X.2015.1128613. eCollection 2016 May.

11.

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Masvidal L, Liang S, Murray S, Larsson O, Kiessling R, Lundqvist A.

Blood. 2016 Sep 15;128(11):1475-89. doi: 10.1182/blood-2016-02-698027. Epub 2016 Jul 27.

12.

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2016 Aug 9;7(32):52061-52084. doi: 10.18632/oncotarget.10474.

13.

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R.

Clin Cancer Res. 2016 Aug 1;22(15):3849-59. doi: 10.1158/1078-0432.CCR-15-1912. Epub 2016 Mar 8.

14.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.

Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV.

Oncoimmunology. 2015 Jul 25;5(1):e1052213. eCollection 2016.

15.

TAP-ing into TIEPPs for cancer immunotherapy.

Kiessling R.

J Clin Invest. 2016 Feb;126(2):480-2. doi: 10.1172/JCI86119. Epub 2016 Jan 19.

16.

Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.

Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, Chmielewski M, Riet T, Abken H, Kiessling R.

J Immunol. 2016 Jan 15;196(2):759-66. doi: 10.4049/jimmunol.1401710. Epub 2015 Dec 16.

17.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

18.

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.

Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M.

PLoS One. 2015 Oct 6;10(10):e0139809. doi: 10.1371/journal.pone.0139809. eCollection 2015.

19.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

20.

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

Pico de Coaña Y, Choudhury A, Kiessling R.

Trends Mol Med. 2015 Aug;21(8):482-91. doi: 10.1016/j.molmed.2015.05.005. Epub 2015 Jun 16. Review.

PMID:
26091825
21.

Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.

Ligtenberg MA, Çınar Ö, Holmdahl R, Mougiakakos D, Kiessling R.

PLoS One. 2015 Jun 15;10(6):e0129786. doi: 10.1371/journal.pone.0129786. eCollection 2015.

22.

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A.

Eur J Immunol. 2015 Jun;45(6):1783-93. doi: 10.1002/eji.201444885. Epub 2015 Apr 17.

23.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

24.

Serendipity. Coincidence. Luck.

Kiessling R.

Crit Rev Oncog. 2014;19(1-2):15-9. Review. No abstract available.

PMID:
25199215
25.

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I, Lövgren T, Adamson L, Nyström M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R.

Cancer Immunol Immunother. 2014 Oct;63(10):1061-71. doi: 10.1007/s00262-014-1575-2. Epub 2014 Jul 4.

PMID:
24993563
26.

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.

Pico de Coaña Y, Masucci G, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2014 Sep;63(9):977-83. doi: 10.1007/s00262-014-1570-7. Epub 2014 Jun 26.

PMID:
24966003
27.

Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

Ishikawa T, Wondimu Z, Oikawa Y, Gentilcore G, Kiessling R, Egyhazi Brage S, Hansson J, Patarroyo M.

Matrix Biol. 2014 Sep;38:69-83. doi: 10.1016/j.matbio.2014.06.002. Epub 2014 Jun 18.

28.

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.

Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A.

Clin Cancer Res. 2014 Aug 1;20(15):4096-106. doi: 10.1158/1078-0432.CCR-14-0635. Epub 2014 Jun 6.

29.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, Masucci GV, Kiessling R.

Cancer Immunol Res. 2013 Sep;1(3):158-62. doi: 10.1158/2326-6066.CIR-13-0016. Epub 2013 Aug 2. Erratum in: Cancer Immunol Res. 2013 Dec;1(6):438.

30.

Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.

Mao Y, Poschke I, Kiessling R.

J Intern Med. 2014 Aug;276(2):154-70. doi: 10.1111/joim.12229. Epub 2014 Mar 24. Review.

31.

Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.

Kiessling R, Mao Y, Pico de Coaña Y.

Clin Cancer Res. 2014 Mar 15;20(6):1401-3. doi: 10.1158/1078-0432.CCR-13-3388. Epub 2014 Feb 13. Review.

32.

The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.

Mimura K, Shiraishi K, Mueller A, Izawa S, Kua LF, So J, Yong WP, Fujii H, Seliger B, Kiessling R, Kono K.

J Immunol. 2013 Dec 15;191(12):6261-72. doi: 10.4049/jimmunol.1301597. Epub 2013 Nov 15.

33.

Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes.

Poschke I, Mao Y, Kiessling R, de Boniface J.

J Transl Med. 2013 Nov 16;11:290. doi: 10.1186/1479-5876-11-290.

34.

HLA-dependent tumour development: a role for tumour associate macrophages?

Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, Masucci GV.

J Transl Med. 2013 Oct 6;11:247. doi: 10.1186/1479-5876-11-247. Review.

35.

The two sides of HER2/neu: immune escape versus surveillance.

Seliger B, Kiessling R.

Trends Mol Med. 2013 Nov;19(11):677-84. doi: 10.1016/j.molmed.2013.08.003. Epub 2013 Sep 12. Review.

PMID:
24035606
36.

NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.

Ligtenberg MA, Rojas-Colonelli N, Kiessling R, Lladser A.

Hum Vaccin Immunother. 2013 Oct;9(10):2189-95. doi: 10.4161/hv.25699. Epub 2013 Jul 24.

37.

Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.

Kono K, Mimura K, Kiessling R.

Cell Death Dis. 2013 Jun 20;4:e688. doi: 10.1038/cddis.2013.207. Review.

38.

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R.

Cancer Res. 2013 Jul 1;73(13):3877-87. doi: 10.1158/0008-5472.CAN-12-4115. Epub 2013 Apr 30.

39.

Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.

Jitschin R, Mougiakakos D, Von Bahr L, Völkl S, Moll G, Ringden O, Kiessling R, Linder S, Le Blanc K.

Stem Cells. 2013 Aug;31(8):1715-25. doi: 10.1002/stem.1386.

40.

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients.

de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I.

Oncoimmunology. 2012 Nov 1;1(8):1305-1312.

41.

Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells.

Kiessling R, Okita R, Mougiakakos D, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kono K.

Oncoimmunology. 2012 Oct 1;1(7):1200-1201.

42.

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression.

Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M, Maruyama T, Kawaguchi Y, Inoue S, Kawasaki T, Choudhury A, Katoh R, Fujii H, Kiessling R, Kono K.

Oncoimmunology. 2012 Oct 1;1(7):1104-1110.

43.

Comparative expression profiling of distinct T cell subsets undergoing oxidative stress.

Lichtenfels R, Mougiakakos D, Johansson CC, Dressler SP, Recktenwald CV, Kiessling R, Seliger B.

PLoS One. 2012;7(7):e41345. doi: 10.1371/journal.pone.0041345. Epub 2012 Jul 20.

44.

On the armament and appearances of human myeloid-derived suppressor cells.

Poschke I, Kiessling R.

Clin Immunol. 2012 Sep;144(3):250-68. doi: 10.1016/j.clim.2012.06.003. Epub 2012 Jun 20. Review.

PMID:
22858650
45.

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.

Masucci GV, Wersäll P, Kiessling R, Lundqvist A, Lewensohn R.

J Transl Med. 2012 May 22;10:104. doi: 10.1186/1479-5876-10-104.

46.

HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.

Recktenwald CV, Leisz S, Steven A, Mimura K, Müller A, Wulfänger J, Kiessling R, Seliger B.

J Biol Chem. 2012 Jul 13;287(29):24320-9. doi: 10.1074/jbc.M111.334425. Epub 2012 May 11.

47.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

48.

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV.

Cancer Immunol Immunother. 2012 Aug;61(8):1243-53. doi: 10.1007/s00262-012-1201-0. Epub 2012 Jan 19.

PMID:
22258792
49.

High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Mougiakakos D, Okita R, Ando T, Dürr C, Gadiot J, Ichikawa J, Zeiser R, Blank C, Johansson CC, Kiessling R.

J Mol Med (Berl). 2012 Aug;90(8):935-44. doi: 10.1007/s00109-012-0857-4. Epub 2012 Jan 17.

PMID:
22249522
50.

First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.

Choudhury A, Höglund P, Kiessling R, Kärre K, Lundqvist A, Malmberg K, Mellstedt H, Scheynius A, Winqvist O, Osterborg A.

Cancer Immunol Immunother. 2012 Apr;61(4):587-91. doi: 10.1007/s00262-011-1177-1. Epub 2012 Jan 15. No abstract available.

PMID:
22246566

Supplemental Content

Loading ...
Support Center